Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
28.35
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Mar 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
32
33
Next >
4 Analysts Have This to Say About Teva Pharmaceutical Indus
↗
May 12, 2022
Over the past 3 months, 4 analysts have published their opinion on Teva Pharmaceutical Indus (NYSE:TEVA) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting
May 12, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg
↗
May 11, 2022
Via
Benzinga
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
May 10, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Why Generic Drugs Giant Teva Pharmaceutical Just Cut Its 2022 Outlook
↗
May 03, 2022
Foreign exchange rates are weighing heavily on sales, according to the firm's CEO.
Via
Investor's Business Daily
FDA Rejects Teva - MedinCell's Schizophrenia Candidate
↗
April 20, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022
↗
May 04, 2022
Upgrades
Via
Benzinga
Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise
↗
May 03, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
↗
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Recap: Teva Pharmaceutical Q1 Earnings
↗
May 03, 2022
Teva Pharmaceutical Indus (NYSE:TEVA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Teva Reports First Quarter 2022 Financial Results
May 03, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
↗
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
Earnings Scheduled For May 3, 2022
↗
May 03, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Via
Benzinga
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
May 02, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters
↗
April 25, 2022
Via
Benzinga
JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters
↗
April 20, 2022
Via
Benzinga
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
↗
April 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
April 19, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
What Were Your Best And Worst Stock Buys? What Does The Zinger Nation Think?
↗
April 06, 2022
Admitting to success is a lot easier than failure and when it comes to stocks, not only is there money involved, but also questioning your — or your advisor's — judgment. And then there is the advice...
Via
Benzinga
Good and Bad stock news
↗
April 05, 2022
Microsoft is down because of an FTC investigation of its possible anti-competitive moves.
Via
Talk Markets
Futures Slide To Overnight Lows As Algos Spooked By EU Ban On Russian Coal
↗
April 05, 2022
After initially trading sharply higher around the European open, US stock futures dropped to session lows as traders digested the latest developments in the Ukraine war.
Via
Talk Markets
Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022
April 04, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: Reuters
↗
April 04, 2022
West Virginia's attorney general urged a judge to hold Johnson & Johnson (NYSE: JNJ), Teva Pharmaceuticals Industries Ltd (NYSE: TEVA), and AbbVie Inc's (NYSE:
Via
Benzinga
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting
April 01, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2022
↗
April 05, 2022
Upgrades
Via
Benzinga
CVS Health, Teva Settle Florida State's Opioid-Related Claims: Report
↗
March 30, 2022
Florida has reached more than $878 million in settlements with CVS Health Corp (NYSE: CVS) and three drug companies to resolve claims and avert a trial next month over their roles in fueling an opioid...
Via
Benzinga
Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims
March 30, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Monday Markets News
↗
March 28, 2022
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.
Via
Talk Markets
Friday Markets News
↗
March 25, 2022
Methane leaks in the Permian Basin are 6 times higher than estimates.
Via
Talk Markets
Rhode Island Announces $107M Opioid Settlements With Teva, Allergan: Reuters
↗
March 22, 2022
Rhode Island's attorney general announced settlements worth $107 million against Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and AbbVie Inc's (NYSE: ABBV) Allergan unit to resolve claims over
Via
Benzinga
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.